Press release
Her2+ Gastric Cancer Market Report 2032: Epidemiology Insights, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sa
Her2+ Gastric Cancer Market Report 2032
DelveInsight's "Her2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032 [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] report offers an in-depth understanding of the Her2+ Gastric Cancer, historical and forecasted epidemiology as well as the Her2+ Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Her2+ Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Her2+ Gastric Cancer Market Forecast [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Some of the key facts of the Her2+ Gastric Cancer Market Report:
*
The Her2+ Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
*
Key Her2+ Gastric Cancer Companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others
*
Key Her2+ Gastric Cancer Therapies: SHR-A1811, Cinrebafusp alfa, BI-1607, and others
*
In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted Breakthrough Therapy designation to KN026, a HER2 bispecific antibody, in combination with chemotherapy for the treatment of HER2-positive gastric cancer, including gastroesophageal junction cancer. This designation underscores the potential of KN026 as a promising treatment option for this aggressive cancer type, expediting its development and regulatory review process.
*
In December 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved by the European Union (EU) as a monotherapy for adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously undergone a trastuzumab-based regimen. This approval provides a significant new treatment option for patients with advanced HER2-positive gastric cancer who have limited therapeutic alternatives.
*
The Her2+ Gastric Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Her2+ Gastric Cancer pipeline products will significantly revolutionize the Her2+ Gastric Cancer market dynamics.
Her2+ Gastric Cancer Overview
HER2-positive gastric cancer, also known as HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, is a specific type of stomach cancer characterized by the overproduction of the human epidermal growth factor receptor 2 (HER2) protein. This form of cancer represents a significant proportion of gastric cancer cases and is associated with distinct clinical and pathological features.
HER2 plays a key role in regulating cell growth and division under normal conditions. However, in HER2-positive gastric cancer, the overexpression of this protein leads to uncontrolled cell proliferation, contributing to the formation and growth of tumors.
The identification of HER2 overexpression in gastric cancer has had a profound impact on treatment strategies, as therapies targeting HER2 have shown the ability to improve patient outcomes. These treatments are specifically designed to block the HER2 protein's activity, disrupting the signals that drive cancer cell growth and survival.
Key therapeutic options for HER2-positive gastric cancer include:
1. HER2-Targeted Therapy: Central to the treatment of HER2-positive gastric cancer is the use of HER2-targeted therapies such as trastuzumab (Herceptin), pertuzumab, and trastuzumab deruxtecan. These therapies are often combined with chemotherapy and have been shown to improve both overall survival and progression-free survival in patients with this cancer subtype.
2. Chemotherapy: Chemotherapy is commonly used alongside HER2-targeted therapies and includes drugs such as fluoropyrimidines, platinum-based agents, and taxanes. These chemotherapy agents help enhance the effectiveness of treatment and manage cancer progression.
3. Surgical Intervention: For patients with localized or resectable HER2-positive gastric cancer, surgery may be an option. This involves the removal of the tumor and nearby lymph nodes. Post-surgery, adjuvant chemotherapy or HER2-targeted therapy may be administered to reduce the risk of recurrence.
4. Radiation Therapy: In cases of locally advanced or inoperable HER2-positive gastric cancer, radiation therapy may be used, often in combination with chemotherapy or surgery, to shrink tumors and destroy cancer cells.
Effective management of HER2-positive gastric cancer requires a multidisciplinary approach, involving oncologists, surgeons, and radiation oncologists. Treatment plans are customized to the individual, considering factors such as the tumor's stage, the patient's overall health, and the treatment goals.
Thanks to the early detection of HER2-positive gastric cancer and the availability of HER2-targeted therapies, patient outcomes have significantly improved. However, ongoing research is critical to refine treatment strategies and further enhance long-term survival rates.
Her2+ Gastric Cancer Epidemiology [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Her2+ Gastric Cancer Epidemiology Segmentation:
The Her2+ Gastric Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Her2+ Gastric Cancer
*
Prevalent Cases of Her2+ Gastric Cancer by severity
*
Gender-specific Prevalence of Her2+ Gastric Cancer
*
Diagnosed Cases of Episodic and Chronic Her2+ Gastric Cancer
Download the report to understand which factors are driving Her2+ Gastric Cancer epidemiology trends @ Her2+ Gastric Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Her2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Her2+ Gastric Cancer market or expected to get launched during the study period. The analysis covers Her2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Her2+ Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Her2+ Gastric Cancer Therapies
*
SHR-A1811, Cinrebafusp alfa, BI-1607, and others.
Her2+ Gastric Cancer Key Companies
*
Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others.
Discover more about therapies set to grab major Her2+ Gastric Cancer market share @ Her2+ Gastric Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Scope of the Her2+ Gastric Cancer Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Her2+ Gastric Cancer Companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others
*
Key Her2+ Gastric Cancer Therapies: SHR-A1811, Cinrebafusp alfa, BI-1607, and others
*
Her2+ Gastric Cancer Therapeutic Assessment: Her2+ Gastric Cancer current marketed and Her2+ Gastric Cancer emerging therapies
*
Her2+ Gastric Cancer Market Dynamics: Her2+ Gastric Cancer market drivers and Her2+ Gastric Cancer market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Her2+ Gastric Cancer Unmet Needs, KOL's views, Analyst's views, Her2+ Gastric Cancer Market Access and Reimbursement
Table of Contents
1. Her2+ Gastric Cancer Market Report Introduction
2. Executive Summary for Her2+ Gastric Cancer
3. SWOT analysis of Her2+ Gastric Cancer
4. Her2+ Gastric Cancer Patient Share (%) Overview at a Glance
5. Her2+ Gastric Cancer Market Overview at a Glance
6. Her2+ Gastric Cancer Disease Background and Overview
7. Her2+ Gastric Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Her2+ Gastric Cancer
9. Her2+ Gastric Cancer Current Treatment and Medical Practices
10. Her2+ Gastric Cancer Unmet Needs
11. Her2+ Gastric Cancer Emerging Therapies
12. Her2+ Gastric Cancer Market Outlook
13. Country-Wise Her2+ Gastric Cancer Market Analysis (2019-2032)
14. Her2+ Gastric Cancer Market Access and Reimbursement of Therapies
15. Her2+ Gastric Cancer Market Drivers
16. Her2+ Gastric Cancer Market Barriers
17. Her2+ Gastric Cancer Appendix
18. Her2+ Gastric Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Her2+ Gastric Cancer Pipeline
"Her2+ Gastric Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Her2+ Gastric Cancer market. A detailed picture of the Her2+ Gastric Cancer pipeline landscape is provided, which includes the disease overview and Her2+ Gastric Cancer treatment guidelines.
Her2+ Gastric Cancer Epidemiology
DelveInsight's 'Her2+ Gastric Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Her2+ Gastric Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-gastric-cancer-market-report-2032-epidemiology-insights-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-roche-elevar-therapeutic-bristolmyers-squibb-merck-daiichi-sa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Her2+ Gastric Cancer Market Report 2032: Epidemiology Insights, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sa here
News-ID: 3774230 • Views: …
More Releases from ABNewswire
Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span b …
The Key Fibrodysplasia Ossificans Progressiva Companies in the market include - Ipsen, Regeneron Pharmaceutical, Biocryst,, and others.
The Fibrodysplasia Ossificans Progressiva market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibrodysplasia Ossificans Progressiva pipeline products will significantly revolutionize the Fibrodysplasia Ossificans Progressiva market dynamics.
DelveInsight's "Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of…
Diabetic Macular Edema Pipeline 2025: MOA and ROA Insights, Clinical Trials Stat …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Macular Edema pipeline constitutes key companies continuously working towards developing Diabetic Macular Edema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Diabetic Macular Edema Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.
The Diabetic Macular…
FIELDBOSS Secures Top Ranking as #1 Elevator Service Software, Recognized for In …
AVENTURA, FL - September 2, 2025 - FIELDBOSS has been named the #1 software for the elevator and escalator industry, winning the top honor from the independent review body, Field Service Software IO. The award distinguishes FIELDBOSS in a competitive market for its ability to manage the complex compliance, maintenance, and operational demands unique to the vertical transportation industry.
The significance of the award is underscored by the selection process. Field…
Progressive Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till …
The Key Progressive Pulmonary Fibrosis Companies in the market include - Boehringer Ingelheim, Bristol-Myers Squibb, Avalyn Pharma Inc., United Therapeutics, Sunshine Lake Pharma, Endeavor Biomedicines, and others.
The Progressive Pulmonary Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Pulmonary Fibrosis pipeline products will significantly revolutionize the Progressive Pulmonary Fibrosis market dynamics.
DelveInsight's "Progressive Pulmonary Fibrosis Market Insights,…
More Releases for Gastric
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driving Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Gastric Ulcers Market Size By 2025?
In the last few years, the market size for gastric ulcers has been expanding notably. It is anticipated to increase from $4.29 billion in 2024 to $4.54 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.9%.…
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driver: Leadi …
How Are the key drivers contributing to the expansion of the gastric ulcers market?
The rising geriatric population is expected to accelerate the growth of the gastric ulcers market. The geriatric population, typically individuals aged 65 and above, is growing due to improvements in healthcare and increased life expectancy. This population is more susceptible to gastric ulcers due to factors like the use of NSAIDs and decreased mucosal protection. For instance,…
Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Ca …
What market dynamics are playing a key role in accelerating the growth of the gastric cancer drugs market?
The rise in obesity and smoking rates has led to an increased prevalence of gastric cancer. Factors like tobacco use and poor dietary habits have been linked to a higher risk of developing this disease. As per data from the Government Digital Service in the UK, it was projected in May 2023 that…
Gastric Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer…
Gastric Function Test Market - Empowering Digestive Health: Gastric Function Tes …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gastric Function Test Market.
Gastric Function Test Market: https://www.growthplusreports.com/report/gastric-function-test-market/9126
The Gastric Function Test Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
The Virtual Gastric Band 101
There’s been a lot in the media recently about the Hypnotic Gastric Band or also known as The Virtual Gastric Band. I get asked a lot about it so thought I’d give a Virtual Gastric Band 101 on what it is, but more importantly what it’s not.
The Virtual Gastric Band - It is a non-surgical technique which uses the power of hypnosis to retrain the person to be satisfied with smaller…
